Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).

导出 LinkOut

翻译打印收藏纠错

作者： Sant P,Chawla ^[1] ; Walter Andree,Tellez ^[1] ; Hripsime,Chomoyan ^[1] ; Chrysler,Valencia ^[1] ; Amir,Ahari ^[1] ; Nadezhda,Omelchenko ^[1] ; Stefan,Makrievski ^[1] ; Don A,Brigham ^[1] ; Victoria,Chua-Alcala ^[2] ; Doris,Quon ^[1] ; Ania,Moradkhani ^[1] ; Erlinda M,Gordon ^[1]

作者单位： Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States. ^[1] Gene and Cell Therapy, Aveni Foundation, Santa Monica, CA, United States. ^[2]

关键词 alkylating agents immunotherapy nivolumab sarcoma talimogene laherparepvec trabectedin

DOI 10.3389/fonc.2023.1116937

PMID 37234994

发布时间 2023-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2023年13卷

1116937页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除